Member Info for Chelsea11

Cleaner - where do you get 1% from?

The RNS is explicit.

“ Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 140,387,037 ordinary shares representing 13.53% of the company”

421 Trades……….and on a Friday! Double Wow!

Out of this world I’d say 🤪

344 Trades. Wow!

Sure and articles dredged from the web would tell me the roast beef I had for lunch must mean I’m now at risk of bad cholesterol, high blood pressure, cardiovascular problems and bowel cancer. That’s not to mention the 2 pints of Moongazer to wash it down. Unfortunately, I couldn’t sit in the sunshine in the pub garden because it was raining lol.

Plenty of things deemed bad for you, all the most enjoyable stuff in life.

Avoid them all or be scared of them and you might as well not be here.

IMO obviously.

Many here will remember Crumbs.

He/she jumped ship and into MKA. That struggled for a while but has now seriously taken off so congratulations Crumbs if you’re still invested there and also looking in here! Was the 5 million you?? 😂

(Not a cross-ramp, just a mention for those who liked Crumbs posts here)

Krafty - now there’s a question!

There are so many variables I’m not going to even attempt to answer that! What I will say is that I always set an exit point when I buy a share and it’s currently some way off 😉

I’ve said many months back that I don’t expect deals that shoot the SP north in 2025, which provoked criticism at the time. For me, 2025 was always going to be a year of harvesting data and any deal is much more likely to come in 2026 - if that data remains attractive. I get the point that the price goes up if the data is compelling and buyers are competing but my belief is that that is outweighed by Scancell needing to prove their products further, in the clinic.

This is unlikely to be a popular viewpoint now, given it wasn’t when I said it months back but it isn’t made with a negative spin. I’ve added to my holding in 2025 while the company has continued to grow both inside and outside the clinic. 2026 for me.

Not formally announced by the Company yet as far as I can see but Scancell will be attending ESMO 2025 in Berlin 17-21 October. Below is an extract from the recently announced Programme (you can find this if you search Varawalla in the Posters section).

1700eTiP - SCOPE Phase 2 clinical trial program evaluating off-the-shelf DNA plasmid vaccines, SCIB1 and iSCIB1+ administered in combination with checkpoint inhibitors in advanced unresectable melanoma.

Here is the link to ESMO 2025 Programme.

https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session

I thought Ruck was the Bureau of Statistics and Probability

Alternatively, you could side with the view of one individual here and believe that the company are making it up as they go along.

Think I’ll take a break from the BB today. 50 odd posts full of AI garbage, monstrously long posts, repetition and of course a lunatic on the loose.

I thought the one thing missing from the presentation was a Coldplay moment.

😂

Violin.

A presentation clearly signposted as contained to one subject and you expect them to cover another topic?

That’s just absurd.

2CV.

Snap!

What I thought was really interesting and possibly quite telling, was the in the background reaction of L’Huillier to the question of accelerated regulatory approval for Phase 2/3, answered really positively by Varawalla.

It was a beaming smirk / smile which I took to mean they’re already some way down that discussion pathway with the likes of the FDA / MHRA.

If you re-read what Nermeen Varawalla says, it is all about iSCIB1+. It’s obvious to me that they already know it is significantly superior to SCIB1 but those on the outside (us) have to wait a little longer for that news to break formally later this year.

Today’s update is a stepping stone towards that and a very positive one and importantly, for the Immunobody platform as a whole.

Chester.

“Eggs” and “Scrambling”

I’m sure you meant it ;-)

Good luck everyone

Scinv v. The Fonz would be Box Office.